Cinchona in the year 1851. Mr. [Thaddäus] Haenke mentioned the existence of cinchona bark on his visit to Yuracares in 1796". (Source: Exploration of the Valley of the Amazon, by Lieut. Lardner Gibbon, USN. Vol.II, Ch.6, pp. 146-47.) The cultivation of cinchona led from the 1890s to a decline in the price of quinine but the quality and production of raw bark by the Dutch in Indonesia led them to dominate world markets. The producers of processed drugs in Europe (especially Germany) however bargained and caused fluctuations in prices which led to a Dutch-led Cinchona Agreement in 1913 that ensured a
Cinchona people. Italian sources spelt Quina as Cina which was a source of confusion with "Smilax" from China. Haggis argued that Qina and Jesuit's bark actually referred to "Myroxylon peruiferum" or Peruvian balsam and that this was an item of importance in Spanish trade in the 1500s. Over time, the bark of the "Myroxylon" was adulterated with the similar looking bark of what we now know as "Cinchona". Gradually the adulterant became the main product that was the key therapeutic ingredient used in malarial therapy. The bark was included as "Cortex Peruanus" in the London Pharmacopoeia in 1677. The "fever tree"